Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Hematologic Malignancies: A Review of Key Clinical Studies

Ian W. Flinn, MD, PhD
Shaji K. Kumar, MD
Farhad Ravandi, MD
Released: September 23, 2020
Back Next

References

  1. Daratumumab [package insert] Horsham, PA: Janssen Biotech, Inc; 2020.
  2. Stadtmauer EA, Pasquini, MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37:589-597.
  3. Cavo M, Gay FM, Patriarca F, et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study. Program and abstracts of the 59th Annual Meeting of the American Society of Hematology; December 9-12, 2017; Atlanta, Georgia. Abstract 401.
  4. Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6:e506.
  5. Wang AY, Lie H. The past, present, and future of CRM1/XPO1 inhibitors. Stem Cell Investig. 2019;6:6.
  6. Selinexor [package insert]. Newton, MA: Karyopharm Therapeutics Inc; 2020.
  7. Bahlis NJ, Sutherland H, White D. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132:2546.
  8. Gasparetto C, Lipe B, Tuchman S, et al. Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM). Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8530.
  9. Gasparetto C, Lentzsch S, Schiller GJ, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8510.
  10. Isatuximab-irfc [package insert]. Bridgewater, N:. Sanofi-Aventis US; 2020.
  11. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207.
  12. Lee HC, Cohen AD, Chari A, et al. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8519.
  13. Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130:2392.
  14. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726-1737.
  15. Mailankody S, Jakubowiak AJ, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8504.
  16. Chao MP, Weissman IL, Majetie R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225-232.
  17. Majeti R, Chao, MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286-299.
  18. Takahashi K, Patel K, Bueso-Ramos C, et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016;7:4172-14187.
  19. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Med. 2015;2:178-184.
  20. Heuser M, Araujo Cruz MM, Goparaju R, et al. Enigmas of IDH mutations in hematology/oncology. Exp Hematol. 2015;43:685-97.
  21. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-731.
  22. Shih AH, Shank KR, Meydan C, et al. AG-221, a small molecule mutant IDH2 inhibitor remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Blood. 2014;124:437.
  23. Enasidenib [package insert]. Summit, NJ: Celgene Corporation; 2019.
  24. Galkin M, Jonas BA. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core Evid. 2019;14:3-17.
  25. Godwin CD. Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855-1868.
  26. Subklewe M, Stein A, Walter R, et al. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Program and abstracts of the 58th Annual meeting of the American Society of Hematology; December 7-10, 2016; Orlando, Florida. Abstract 833.
  27. Westervelt P, Cortes JE, Altman JK, et al. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33/CD3 T-cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML). Program and abstracts of the 58th Annual Meeting of the American Society of Hematology; December 7-10, 2016; Orlando, Florida. Abstract 834.
  28. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
  29. Blinatumomab [package inset] Thousand Oaks, CA: Amgen Inc; 2020.
  30. Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Program and abstracts of the 58th Annual Meeting of the American Society of Hematology; December 7-10, 2016; Orlando, Florida. Abstract LBA-3.
  31. Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 2018;9:300-305.
  32. Ivosidenib [package insert] Cambridge, MA: Agios Pharmaceuticals; 2019.
  33. Venetoclax [package insert]. Chicago, IL: AbbVie Inc; 2020.
  34. FDA.gov  FDA approves venetoclax in combination for AML in adults.  https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults
  35. Pembrolizumab [package insert]. Kenilworth, NJ: Merck Sharp & Dohme Corp; 2020.
  36. Nivolumab [package insert]. New York, NY: Bristol-Myers Squibb; 2020.
  37. Moskowitz AJ, Herrera AF, Beavan AW. Relapsed and refractory classical Hodgkin Lymphoma: keeping pace with novel agents and new options for salvage therapy. American Society of Clinical Oncology Educational Book. 2019;39:477-486.
  38. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183-2189.
  39. Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8005.
  40. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13:578-591.
  41. Argyropoulos KV, Vogel R, Ziegler C, et al. Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia. 2016;30:1116-1125.
  42. Zanubrutinib [package insert]. San Mateo, CA: BeiGene; 2019.
  43. Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62:7923-7940.
  44. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851-859.
  45. Tam CSL, Opat S, D’Sa S, et al. ASPEN: results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM). Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8007.
  46. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363:240-252.
  47. Acalabrutinib [package insert]. Wilmington, DE: AstraZeneca; 2019.
  48. Ghia P, Pluta A, Wach M, et al. Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results. Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8015.
  49. Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability. Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8024.
  50. Furman RR, Byrd JC, Owen RG, et al. Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: pooled analysis from clinical trials. Program and abstracts of the of the 2020 American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2020. Abstract 8064.
  51. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353-1363.
  52. Lugtenburg P, Mous R, Clausen MR, et al. First-in-human phase 1/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody®-CD3×CD20) in b-cell non-Hodgkin lymphomas. Program and abstracts of the 61st Annual Meeting of the American Society of Hematology; December 7-10, 2019; Orlando, Florida. Abstract 758.
Back Next
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings